Skip to main content
Premium Trial:

Request an Annual Quote

Pharmaxis Taps Dotmatics Software for Preclinical Research Data Management

Premium

Cheminformatics firm Dotmatics said this week that Pharmaxis, a specialty pharmaceutical company, has selected its software suite to support preclinical research data management.

Dotmatics' product suite includes Browser, an interactive dashboard that allows users to integrate and view research data from multiple sources; and Vortex, an application that provides an environment for predictive analytics, visualization, and data analysis.

Pharmaxis, which focuses on developing therapies for chronic respiratory diseases, selected the Dotmatics platform after considering options from a number of software companies, Wolfgang Jarolimek, Pharmaxis's head of drug discovery, said in a statement.

Features that informed its decision to go with Dotmatics's tools include support for analysis of plate-based data, the ability to accept data uploads from Excel spreadsheets, and the ability to enable Pharmaxis's scientists to drill down into large datasets, he said.

Last September, UK-based Dotmatics moved its East Coast office to a large facility in Boston, Mass., to make room for its expanding sales and support teams as well as new hires. At the time, the company also said it was looking to increase its footprint in markets outside the life science including the chemical-research space, oil and gas industries, and consumer products (BI 9/9/2011).

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.